August 23, 2017
Nativis to Present at 19th Annual Rodman & Renshaw Global Investment Conference
SEATTLE August 23, 2017 – Nativis, Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, being held on September 10-12, 2017 at The Lotte New York Palace Hotel in New York City.
Chris E. Rivera, Nativis President and Chief Executive Officer, will provide an overview and update of the Company’s progress during the first 3 quarters of 2017 and other activities at a live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Earlier this year, Nativis announced it had entered into an exclusive licensing agreement for the development and commercialization of Nativis’ proprietary ultra-low Radio Frequency Energy (ulRFE®) technology for the potential treatment of Glioblastoma Multiforme (GBM) in the Japanese market, with Teijin Limited, a comprehensive Japanese company expanding businesses in high-performance materials, pharmaceuticals, home healthcare, product converting and information technology.
Mr. Rivera will also provide updates on progress being made in Nativis’ US human clinical trial in recurrent GBM, NAT-101, as well as near term strategy for the company.
Institutional investors, who would like to attend the Company’s presentation, please click on the link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Details for the presentation are as follows:
Date: Tuesday, September 12, 2017
Time: 2:35 – 3:00 p.m. EDT
Room: Kennedy II
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive device called Nativis Voyager®. The Company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.
Investor Relations Contact:
Lee Roth / Tram Bui
firstname.lastname@example.org / email@example.com
646-536-7012 / 7035
Media Relations Contact:
Aaron Blank / Amber Benson
firstname.lastname@example.org / email@example.com
206-343-1543Back to News